Harvard Bioscience, Inc.
Harvard Bioscience, Inc. (HBIO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
hbio · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$6.00
-0.2% upside
Low
$6.00
Median: $6 · Last Close: $6.01
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $6.31 | ↑ 5.00% |
1-day model range: $6.25–$6.37. Peak: $6.37 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · HBIO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-16 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2026-03-13 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2025-09-10 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2025-05-13 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2025-04-09 | Keybanc | Downgrade ↓ | Overweight→Sector Weight |
| 2025-04-08 | Keybanc | Downgrade ↓ | Overweight→Sector Weight |
| 2025-03-24 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2023-06-22 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2023-04-26 | Keybanc | Maintains | Overweight→Overweight |
| 2023-04-26 | Benchmark | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Harvard Bioscience, Inc. (HBIO) stock. Of the recent 19 rating actions, 1 were upgrades and 2 were downgrades. 5 analysts currently cover HBIO.
Analyst Recommendation Trends
HBIO analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$94M
↑ 5.8% YoY
Revenue Next Year
$86M
↓ 8.4% YoY
EPS This Year
$0.45
EPS Next Year
$0.30
↓ 33.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast HBIO EPS of $0.45 for the current fiscal year, based on estimates from 1 analysts. The HBIO revenue forecast is $94M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The HBIO stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HBIO price target is $6.00 (-0.2% upside), with an analyst consensus of Buy.
The HBIO short-term stock prediction for tomorrow is $6.31 (+5.00%).
Harvard Bioscience, Inc. trades on NASDAQ under the ticker HBIO. The HBIO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
HBIO forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month HBIO price target is $6.00, with a high forecast of $6.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies -0.2% potential upside from the current price of $6.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.